MD Magazine: Comorbidity Care with SGLT-2 Inhibition

In an interview with MD Magazine® while at  Heart Failure Society of America (HFSA) 2019, DEFINE-HF study chair Mikhail Kosiborod, MD, director of Cardiometabolic Research at Saint Luke’s Mid America Heart Institute, discussed where the clinical understanding of sodium-glucose co-transporter-2 inhibitors—as well as GLP-1 agonists—are stationed headed into the new dapagliflozin data.

Read the full Q&A with MD Magazine, "Mikhail Kosiborod, MD: Comorbidity Care with SGLT-2 Inhibition"